We support research into the personalised treatment of cancer

We promote different pioneering projects in scientific research against cancer.

Our goal: collaborate in projects that improve the treatment of the illness and offer patients the best options in therapy. 

Cancer Molecular Therapy Research Unit (UITM) - Vall d'Hebron Institute of Oncology (VHIO)

The Cancer Molecular Therapy Research Unit (UITM) - "la Caixa" of the VHIO, inaugurated in 2012, is dedicated to carrying out complex clinical trials with drugs in clinical trial stages (Stage I, Stage II and Stage III), focusing on new molecular targets specific to cancer treatment.

The UITM carries out a molecular analysis of patients' tumours in order to select the best treatment possible with available experimental therapies, one step further to achieving the promise of truly individualised medicine.

Access to Cancer Molecular Therapy Research Unit (UITM) - Vall d'Hebron Institute of Oncology (VHIO)
 

"la Caixa" International Program for Cancer Research and Education & International Meetings Program– MSKCC & VHIO

This programme was set up to help the Vall d'Hebron Institute of Oncology (VHIO) and the Memorial Sloan Kettering Cancer Center (MSKCC) to extend their joint work to raise awareness via scholarships and international research meetings, enhancing the complementary strengths of VHIO and MSKCC in the fields of basic cancer research, drug development, diagnosis and clinical trials.

Access to "la Caixa" International Program for Cancer Research and Education & International Meetings Program– MSKCC & VHIO
 

Research in Lung Cancer – Dr. Rosell – ICO

This research project has helped to improve the treatment of tumours altering the EGFR gene and has helped to understand why some become resistant to standard treatments.

The scientific journal The Lancet considers Dr. Rafael Rosell to be a European leader in fighting lung cancer and acknowledges his pioneering work in molecular studies on lung tumours to personalise treatments and further a la carte therapy.
 

Epigenetic prediction of drug response for selecting and optimising cancer therapy – Dr. Manel Esteller –IDIBELL

With the contribution of "la Caixa" Foundation, Doctor Manel Esteller, director of the Epigenetics and Cancer Biology Programme of the Bellvitge Institute of Biomedical Research (IDIBELL), is carrying out a pioneering study on epigenetic prediction of drug response to optimise cancer therapy in patients who no longer respond to standard treatment.

This research aims to define markers of DNA methylation in colon, lung, pancreas and brain cancer cell lines, in order to predict response to new treatments. 

The results of the investigation will directly benefit a hundred patients participating in the clinical project and will be the key to the implementation of the best therapy for each patient to lengthen and improve their quality of life and reduce the impact of treatment toxicity.

Access to Epigenetic prediction of drug response for selecting and optimising cancer therapy – Dr. Manel Esteller –IDIBELL
 

Josep Carreras Research Institute against Leukaemia (IJC)

The IJC is the leading research centre in Europe focusing exclusively on leukaemia and other malignant haematological diseases and one of the few in the world.

The contribution made by the "la Caixa" Foundation to the Josep Carreras Leukaemia Foundation is aimed at supporting the implementation of projects, providing start-up funds for each of the research groups as well as buying laboratory equipment.

Access to Josep Carreras Research Institute against Leukaemia (IJC)
 

Immunotherapy based on the use of dendritic cells in advanced solid tumours, in children and adolescents

Dr Ana Patiño García, director of the Clinical Genetics Unit and head of the laboratory and Paediatric Department.

This project is part of the Children against Cancer programme of Clínica Universidad de Navarra and seeks to improve survival and quality of life of children with high-grade solid tumours, assess the safety of the treatment and its impact on other clinical parameters of efficacy and, finally, to evaluate the biological efficacy of the vaccine through in vitro studies.

The aim is to reduce mortality, predict the development of metastasis and develop new efficacious and non-toxic therapies, to ensure that child oncological patients do not become chronically ill adults because of the treatment received.

Access to Immunotherapy based on the use of dendritic cells in advanced solid tumours, in children and adolescents
 

DNA interaction with Ru organometallic complexes and atomic quantum clusters

In collaboration with the University of Burgos and the University of Santiago.

The main aim of this project is to find new anti-tumour drugs.

With the intention of offering better therapeutic options to patients and increasing their efficiency, new drugs will be researched and developed by studying certain synthetic substances that contain metals and by evaluating how they act when faced with biological molecules. 

Access to DNA interaction with Ru organometallic complexes and atomic quantum clusters
 

Gene therapy for Dravet syndrome. Multi-organ metastasis mechanisms in native lung cancer models for personalized treatment

Foundation for Applied Medical Research (CIMA). Dr Gloria González-Aseguinolaza.

Dravet syndrome is one of the most severe infantile epileptic encephalopathies for patients and their families. It is characterized by frequent prolonged seizures that appear between the age of four and six months in apparently healthy children, and is associated to intellectual impairment and behavioural alterations in later stages.

At present there is no specific treatment, and the treatment habitually used for epilepsy makes symptoms worse. The aim of this project is to analyse how this disease responds to gene therapy and to define what the parameters should be in order to obtain clinically relevant results.

Access to Gene therapy for Dravet syndrome. Multi-organ metastasis mechanisms in native lung cancer models for personalized treatment